Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11. https://doi.org/10.1002/art.37715.

Article  PubMed  CAS  Google Scholar 

Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol. 2008;35:88–95. https://doi.org/10.1007/s12016-008-8075-0.

Article  PubMed  Google Scholar 

Dejaco C, Duftner C, Buttgereit F, Matteson EL. Dasgupta B et al The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatol Oxf Engl. 2017;56:506–15. https://doi.org/10.1093/rheumatology/kew273.

Article  CAS  Google Scholar 

Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672.

Article  PubMed  Google Scholar 

Valent F, Bond M, Cavallaro E, Treppo E, Rosalia Maria DR, Tullio A, Dejaco C, De Vita S. Data linkage analysis of giant cell arteritis in Italy: healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017). Quartuccio Vasc Med Lond Engl. 2020;25(2):150–6. https://doi.org/10.1177/1358863X19886074.

Quartuccio L, Isola M, Bruno D, Treppo E, Gigante L, Angelotti F, et al. Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: a multicenter retrospective controlled study. J Transl Autoimmun. 2020;3:100072. https://doi.org/10.1016/j.jtauto.2020.100072.

Article  PubMed  PubMed Central  Google Scholar 

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–28. https://doi.org/10.1056/NEJMoa1613849.

Article  PubMed  CAS  Google Scholar 

Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatol Oxf Engl. 2012;51:1677–86. https://doi.org/10.1093/rheumatology/kes127.

Article  CAS  Google Scholar 

Carbonella A, Berardi G, Petricca L, Biscetti F, Alivernini S, Bosello SL, et al. Immunosuppressive therapy (methotrexate or cyclophosphamide) in combination with corticosteroids in the treatment of giant cell arteritis: comparison with corticosteroids alone. J Am Geriatr Soc. 2015;64:672–374. https://doi.org/10.1111/jgs.14004.

Article  Google Scholar 

Quartuccio L, Treppo E, Dejaco C. The pre-clinical phase of giant cell arteritis: new clues in the pathogenesis of giant cell arteritis supporting emerging targets. Rheumatol (Oxford). 2023;62(6):2032–34.

Dejaco C, Ramiro S, Bond M, Bosch P, Ponte C, Mackie SL, Bley TA, Blockmans D, Brolin S, Bolek EC, Cassie R, Cid MC, Molina-Collada J, Dasgupta B, Nielsen BD, De Miguel E, Direskeneli H, Duftner C, Hočevar A, Molto A, Schäfer VS, Seitz L, Slart RHJA, Schmidt WA. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83(6):741–51. https://doi.org/10.1136/ard-2023-224543.

Carvajal Alegria G, Nicolas M, van Sleen Y. Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants? Front Immunol. 2023;15(14):1202160. https://doi.org/10.3389/fimmu.2023.1202160.

Article  CAS  Google Scholar 

Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.

Article  PubMed  CAS  Google Scholar 

Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheum. 2022;74:1881–9.

Article  CAS  Google Scholar 

van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, Luqmani RA, Dasgupta B. Novel ultrasonographic Halo score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 2020;79(3):393–9. https://doi.org/10.1136/annrheumdis-2019-216343.

Article  PubMed  CAS  Google Scholar 

Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, Mekinian A. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015;94:e622. https://doi.org/10.1097/MD.0000000000000622.

Article  PubMed  PubMed Central  Google Scholar 

Nienhuis PH, Sandovici M, Glaudemans AW, Slart RH, Brouwer E. Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis. Semin Arthritis Rheum. 2020;50:616–23. https://doi.org/10.1016/j.semarthrit.2020.04.002.

Article  PubMed  CAS  Google Scholar 

Slart RHJA, Glaudemans AWJM, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45:1250–69.

Article  PubMed  PubMed Central  Google Scholar 

Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and c-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheumatism. 2012;41:866–71. https://doi.org/10.1016/j.semarthrit.2011.10.005.

Article  PubMed  CAS  Google Scholar 

Chan FLY, Lester S, Whittle SL, Hill CL. The utility of ESR, CRP and platelets in the diagnosis of GCA. BMC Rheumatol. 2019;3:14. https://doi.org/10.1186/s41927-019-0061-z.

Article  PubMed  PubMed Central  Google Scholar 

Atlas IS, Colley SM, Chia MA. Utility of biomarkers and temporal artery biopsy length for investigating giant cell arteritis in Western Australia. Int J Rheum Dis. 2023;26:286–91. https://doi.org/10.1111/1756-185X.14488.

Article  PubMed  CAS  Google Scholar 

Van Sleen Y, Therkildsen P, Nielsen BD, van der Geest KSM, Hansen I, Heeringa P, et al. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. Arthritis Res Ther. 2022;24:65. https://doi.org/10.1186/s13075-022-02754-5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Oh LJ, Wong E, Andrici J, McCluskey P, Smith JEH, Gill AJ. Full blood count as an ancillary test to support the diagnosis of giant cell arteritis: full blood count in giant cell arteritis. Intern Med J. 2018;48:408–13. https://doi.org/10.1111/imj.13713.

Article  PubMed  CAS  Google Scholar 

Burja B, Feichtinger J, Lakota K, Thallinger GG, Sodin-Semrl S, Kuret T, et al. Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment naïve patients. Clin Rheumatol. 2019;38:317–29. https://doi.org/10.1007/s10.

Article  PubMed  Google Scholar 

O’Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, et al. Regulation of inflammation and angiogenesis in giant cell arteritis by acute-phase serum amyloid a. Arthritis Rheumatol. 2015;67:2447–56. https://doi.org/10.1002/art.39217.

Article  PubMed  CAS  Google Scholar 

Dartevel A, Toussaint B, Trocme C, Arnaud M, Simon N, Faure P, et al. Serum amyloid A as a marker of disease activity in Giant cell arteritis. Autoimmun Rev. 2020;19:102428. https://doi.org/10.1016/j.autrev.2019.102428.

Article  PubMed  Google Scholar 

Wadström K, Jacobsson LTH, Mohammad AJ, Warrington KJ, Matteson EL, Jakobsson ME, et al. Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study. Rheumatol (Oxford). 2023;62(6):2304–11. https://doi.org/10.1093/rheumatology/keac581.

Article  CAS  Google Scholar 

Saut A, Paclet MH, Trocmé C, Toussaint B, Bocquet A, Bouillet L, Baillet A. Serum calprotectin is a marker of disease activity in giant cell arteritis. Autoimmun Rev. 2023;22(12):103469. https://doi.org/10.1016/j.autrev.2023.103469.

Article  PubMed  CAS  Google Scholar 

Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, et al. Serum S100 proteins as a marker of disease activity in large vessel vasculitis: JCR. J Clin Rheumatol. 2018;24:393–5. https://doi.org/10.1097/RHU.0000000000000729.

Article  PubMed  PubMed Central  Google Scholar